- Home
- SNOA vs NCNA Comparison
SNOA vs NCNA Comparison
Compare SNOA & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNOA
- NCNA
- Stock Information
- Founded
- SNOA 1999
- NCNA 1997
- Country
- SNOA United States
- NCNA United Kingdom
- Employees
- SNOA N/A
- NCNA N/A
- Industry
- SNOA Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- SNOA Health Care
- NCNA Health Care
- Exchange
- SNOA Nasdaq
- NCNA Nasdaq
- Market Cap
- SNOA 6.5M
- NCNA 7.6M
- IPO Year
- SNOA 2007
- NCNA 2017
- Fundamental
- Price
- SNOA $3.76
- NCNA $3.63
- Analyst Decision
- SNOA
- NCNA
- Analyst Count
- SNOA 0
- NCNA 0
- Target Price
- SNOA N/A
- NCNA N/A
- AVG Volume (30 Days)
- SNOA 53.7K
- NCNA 324.2K
- Earning Date
- SNOA 11-04-2025
- NCNA 11-24-2025
- Dividend Yield
- SNOA N/A
- NCNA N/A
- EPS Growth
- SNOA N/A
- NCNA N/A
- EPS
- SNOA N/A
- NCNA N/A
- Revenue
- SNOA $16,937,000.00
- NCNA N/A
- Revenue This Year
- SNOA $23.00
- NCNA N/A
- Revenue Next Year
- SNOA $24.59
- NCNA N/A
- P/E Ratio
- SNOA N/A
- NCNA N/A
- Revenue Growth
- SNOA 25.02
- NCNA N/A
- 52 Week Low
- SNOA $1.75
- NCNA $2.78
- 52 Week High
- SNOA $6.92
- NCNA $332.00
- Technical
- Relative Strength Index (RSI)
- SNOA 43.03
- NCNA 40.04
- Support Level
- SNOA $3.73
- NCNA $3.71
- Resistance Level
- SNOA $4.01
- NCNA $4.07
- Average True Range (ATR)
- SNOA 0.22
- NCNA 0.35
- MACD
- SNOA -0.00
- NCNA -0.16
- Stochastic Oscillator
- SNOA 44.32
- NCNA 0.98
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.